Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena RM) in NSCLC Patients Refractory to Conventional Treatment Modalities
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2014
At a glance
- Drugs Antroquinonol (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Golden Biotechnology Corporation
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2013 Planned end date changed from 1 Mar 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.